 |
160 Products |  |
813 Diseases | | 160 Products |
|
1586 Trials |  |
77739 News |  |
| «12...884885886887888889890891892893894...897898» |
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
New P3 trial: Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis (clinicaltrials.gov) - Sep 19, 2012
P3, N=240, Recruiting, Sponsor: Celgene Corporation
- | Trial completion: Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=222, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Surgery: Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Sep 19, 2012
P3, N=214, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial initiation date: Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis (clinicaltrials.gov) - Sep 18, 2012
P4, N=200, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed Initiation date: Jun 2010 --> Nov 2010
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment change: Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Sep 18, 2012
P4, N=20, Active, not recruiting, Sponsor: University of Maryland
Initiation date: Jun 2010 --> Nov 2010 N=40 --> 20
- ||| Aimovig (erenumab-aooe) / Amgen, Novartis
New P1 trial: Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients (clinicaltrials.gov) - Sep 18, 2012
P1, N=60, Completed, Sponsor: Amgen
- ||||||| Prolia (denosumab) / Amgen
Trial completion: A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates (clinicaltrials.gov) - Sep 18, 2012
P3, N=833, Completed, Sponsor: Amgen
N=40 --> 20 Active, not recruiting --> Completed
- ||||| Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment change: Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) (clinicaltrials.gov) - Sep 16, 2012
P3, N=60, Active, not recruiting, Sponsor: Raptor Pharmaceuticals Inc.
Active, not recruiting --> Completed N=30 --> 60
- | Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment change: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon (clinicaltrials.gov) - Sep 16, 2012
P3, N=43, Completed, Sponsor: Raptor Pharmaceuticals Inc.
N=30 --> 60 N=20 --> 43
- ||||| Procysbi (cysteamine bitartrate delayed release) / Amgen
Enrollment closed: Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) (clinicaltrials.gov) - Sep 16, 2012
P3, N=60, Active, not recruiting, Sponsor: Raptor Pharmaceuticals Inc.
N=20 --> 43 Recruiting --> Active, not recruiting
- || Procysbi (cysteamine bitartrate delayed release) / Amgen
Trial completion: Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon (clinicaltrials.gov) - Sep 16, 2012
P3, N=43, Completed, Sponsor: Raptor Pharmaceuticals Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| motesanib (AMG 706) / Takeda
Trial completion, Metastases: A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer (clinicaltrials.gov) - Sep 16, 2012
P2, N=184, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Herceptin (trastuzumab) / Roche
Trial completion: Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial (clinicaltrials.gov) - Sep 12, 2012
P1/2, N=40, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | motesanib (AMG 706) / Takeda
Trial termination, Combination therapy, Metastases: A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer (clinicaltrials.gov) - Sep 11, 2012
P2, N=282, Terminated, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Sponsor decision to close study
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=8, Terminated, Sponsor: University of California, San Francisco
Active, not recruiting --> Terminated; Sponsor decision to close study Completed --> Terminated; lack of efficacy
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=8, Terminated, Sponsor: University of California, San Francisco
Completed --> Terminated; lack of efficacy N=10 --> 8
- | motesanib (AMG 706) / Takeda
Trial completion, Combination therapy, Metastases: Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer (clinicaltrials.gov) - Sep 11, 2012
P1, N=46, Completed, Sponsor: Amgen
N=10 --> 8 Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia (clinicaltrials.gov) - Sep 10, 2012
P1, N=55, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed N=24 --> 55
- ||||| Ibrance (palbociclib) / Pfizer
New P1/2 trial: A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer (clinicaltrials.gov) - Sep 10, 2012
P1/2, N=58, Active, not recruiting, Sponsor: Pfizer
- | prezalumab (AMG 557) / Amgen, AstraZeneca
New P1 trial: Safety Study of AMG 557 in Subjects With Lupus Arthritis (clinicaltrials.gov) - Sep 10, 2012
P1, N=40, Recruiting, Sponsor: Amgen
- buparlisib (AN2025) / Adlai Nortye, Vectibix (panitumumab) / Amgen
Enrollment open: P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. (clinicaltrials.gov) - Sep 10, 2012
P1/2, N=40, Recruiting, Sponsor: NCIC Clinical Trials Group
N=24 --> 55 Not yet recruiting --> Recruiting
- | Trial completion: Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia (clinicaltrials.gov) - Sep 10, 2012
P1, N=55, Completed, Sponsor: Case Comprehensive Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Vectibix (panitumumab) / Amgen
Trial suspension: NEOREC-1: Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer (clinicaltrials.gov) - Sep 9, 2012
P2, N=48, Suspended, Sponsor: National Center for Tumor Diseases, Heidelberg
Active, not recruiting --> Completed Recruiting --> Suspended
- Neulasta (pegfilgrastim) / Roche, Rituxan (rituximab) / Roche
New P2 trial, Combination therapy: Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma (clinicaltrials.gov) - Sep 6, 2012
P2, N=20, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
- | Rituxan (rituximab) / Roche
Enrollment change: CALGB-50303: Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 5, 2012
P3, N=523, Recruiting, Sponsor: Cancer and Leukemia Group B
Recruiting --> Suspended N=170 --> 523
- Rituxan (rituximab) / Roche
Enrollment closed: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma (clinicaltrials.gov) - Sep 5, 2012
P2, N=70, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=170 --> 523 Recruiting --> Active, not recruiting
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission (clinicaltrials.gov) - Sep 5, 2012
P2, N=61, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Vectibix (panitumumab) / Amgen
Enrollment closed: Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer (clinicaltrials.gov) - Sep 4, 2012
P2, N=64, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- dilanubicel (NLA101) / Nohla Therap
Enrollment closed, Combination therapy: Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - Sep 3, 2012
P1, N=40, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- Nplate (romiplostim) / Amgen, Kyowa Kirin
New P2 trial: Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (clinicaltrials.gov) - Aug 29, 2012
P2, N=14, Recruiting, Sponsor: New York University School of Medicine
- Vectibix (panitumumab) / Amgen
Enrollment open: Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus (clinicaltrials.gov) - Aug 29, 2012
P1/2, N=45, Recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Suspended --> Active, not recruiting Not yet recruiting --> Recruiting
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change, Real-world evidence, Real-world: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry (clinicaltrials.gov) - Aug 27, 2012
P4, N=1, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting N=8227 --> 1
- docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Metastases: Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma (clinicaltrials.gov) - Aug 27, 2012
P2, N=40, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=8227 --> 1 Not yet recruiting --> Recruiting
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Real-world evidence, Real-world: Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry (clinicaltrials.gov) - Aug 27, 2012
P4, N=1, Completed, Sponsor: Pfizer
Not yet recruiting --> Recruiting Enrolling by invitation --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, Metastases: Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors (clinicaltrials.gov) - Aug 23, 2012
P2, N=74, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting
- | Neulasta (pegfilgrastim) / Roche
New P2 trial: Dose Dense TC + Pegfilgrastim Support for Breast Cancer (clinicaltrials.gov) - Aug 21, 2012
P2, N=41, Completed, Sponsor: University of Wisconsin, Madison
- carboplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment closed: Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov) - Aug 21, 2012
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen
Trial completion: Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 21, 2012
P2, N=68, Completed, Sponsor: Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
Enrollment change: Can We Miss Pigmented Lesions in Psoriasis Patients? (clinicaltrials.gov) - Aug 20, 2012
P4, N=6, Completed, Sponsor: University of Alabama at Birmingham
Recruiting --> Completed N=10 --> 6
- Enrollment open: REDES-TNF: Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (clinicaltrials.gov) - Aug 20, 2012
P4, N=190, Recruiting, Sponsor: Spanish Clinical Pharmacology Society
N=10 --> 6 Not yet recruiting --> Recruiting
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Can We Miss Pigmented Lesions in Psoriasis Patients? (clinicaltrials.gov) - Aug 20, 2012
P4, N=6, Completed, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Vectibix (panitumumab) / Amgen, motesanib (AMG 706) / Takeda
Trial completion: Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 20, 2012
P1, N=119, Completed, Sponsor: Amgen
Recruiting --> Completed Active, not recruiting --> Completed
- Enbrel (etanercept) / Pfizer, Amgen
Trial completion, Surgery: Preoperative Etanercept Before Inguinal Hernia Surgery (clinicaltrials.gov) - Aug 19, 2012
P=N/A, N=77, Completed, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Enrollment change: Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Aug 16, 2012
P4, N=13, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Enrolling by invitation --> Completed N=144 --> 13
- ||||| Vectibix (panitumumab) / Amgen
New P2 trial, HEOR: Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer (clinicaltrials.gov) - Aug 16, 2012
P2, N=74, Recruiting, Sponsor: AIO-Studien-gGmbH
- | trebananib (AMG 386) / Amgen
New P2 trial, Combination therapy, Metastases: Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 15, 2012
P2, N=36, Active, not recruiting, Sponsor: Amgen
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Enrollment change: Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) (clinicaltrials.gov) - Aug 14, 2012
P2/3, N=30, Terminated, Sponsor: Medical College of Wisconsin
N=144 --> 13 N=75 --> 30
- Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Journal: ESAs, Reticulocyte Dynamic and Hemoglobin Variability (clinicaltrials.gov) - Aug 14, 2012
P=N/A, N=31, Completed, Sponsor: Ospedale Regionale di Locarno
- |||||| Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Enrollment open: START-CKD: Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease (clinicaltrials.gov) - Aug 14, 2012
P3, N=750, Recruiting, Sponsor: Amgen
N=75 --> 30 Not yet recruiting --> Recruiting
- | motesanib (AMG 706) / Takeda
Trial termination, Combination therapy, Metastases: MONET1-MOtesanib NSCLC Efficacy and Tolerability Study (clinicaltrials.gov) - Aug 12, 2012
P3, N=1450, Terminated, Sponsor: Amgen
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Amgen discontinued the development of AMG706 because 20050201 did not meet its primary objective.